Clinical Research Directory
Browse clinical research sites, groups, and studies.
Surfactant Using a Supraglottic Airway Device in Late Preterm to Early Term Infants
Sponsor: Sharp HealthCare
Summary
The purpose of this research is to learn new information that may help other infants that have respiratory distress syndrome and need breathing support after birth. The goal of this research is to see if continuous positive airway pressure (CPAP) alone or CPAP with surfactant administration through a less invasive method via an Airway Device (supraglottic airway device) temporarily placed above the vocal cords is better for treating respiratory distress syndrome in late preterm and early term infants.
Official title: Surfactant Prophylaxis in LAte Preterm to Early Term Infants Using a Supraglottic Airway Device to Help Improve Outcomes
Key Details
Gender
All
Age Range
33 Weeks - 38 Weeks
Study Type
INTERVENTIONAL
Enrollment
422
Start Date
2025-10-01
Completion Date
2031-06-30
Last Updated
2025-09-16
Healthy Volunteers
No
Interventions
Surfactant Administration Through Laryngeal or Supraglottic Airway (SALSA)
A single dose of surfactant will be given via Surfactant Administration Through Laryngeal or Supraglottic Airways (SALSA). A supraglottic airway device will be used as a standardized procedure for surfactant administration via SALSA using an AirLife Air-Q.
Continuous Positive Airway Pressure (CPAP)
Infants to receive continuation of non-invasive respiratory support will remain on continuous positive airway pressure (CPAP).
Locations (3)
Sharp Chula Vista Medical Center
Chula Vista, California, United States
Sharp Grossmont Hospital
La Mesa, California, United States
Sharp Mary Birch Hospital for Women & Newborns
San Diego, California, United States